1. Home
  2. FC vs TENX Comparison

FC vs TENX Comparison

Compare FC & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Covey Company

FC

Franklin Covey Company

HOLD

Current Price

$24.37

Market Cap

267.7M

ML Signal

HOLD

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$12.98

Market Cap

317.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FC
TENX
Founded
1983
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
267.7M
317.8M
IPO Year
1994
2001

Fundamental Metrics

Financial Performance
Metric
FC
TENX
Price
$24.37
$12.98
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$26.00
$29.67
AVG Volume (30 Days)
68.7K
923.9K
Earning Date
04-01-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$267,067,000.00
N/A
Revenue This Year
$3.15
N/A
Revenue Next Year
$4.04
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.16
$5.67
52 Week High
$25.50
$18.38

Technical Indicators

Market Signals
Indicator
FC
TENX
Relative Strength Index (RSI) 60.18 61.96
Support Level $23.07 $13.16
Resistance Level $25.50 $14.15
Average True Range (ATR) 1.22 0.80
MACD -0.08 0.30
Stochastic Oscillator 65.83 83.56

Price Performance

Historical Comparison
FC
TENX

About FC Franklin Covey Company

Franklin Covey Co is a company focused on organizational performance improvement. It operates in the business segments of North America, International Direct Offices, International Licensees, Education Division. The company derives revenue from providing training and consulting services and through the sale of books, audio media, and other related products. It has a business presence in Australia, New Zealand, China, Japan, the United Kingdom, Ireland, and Other countries.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: